B
Beijing Lingfu Biotechnology
A company dedicated to exploring experimental animal resources, animal model technology and innovative scientific research services
About Beijing Lingfu Biotechnology
Beijing Lingfu Biotechnology Co., Ltd. operates as a specialized contract research organization (CRO) focused on providing experimental animal models and related scientific research services. Established in 2021 and headquartered in Beijing, China, the company has positioned itself as a key service provider for the burgeoning biomedical industry.
The company was incubated and jointly established by Beijing Saifu Pharmaceutical Research Institute Co., Ltd., Beijing Renyuan Xinsheng Biotechnology Co., Ltd., and a team of experts from the experimental animal sector. This strategic foundation provides Lingfu with a substantial knowledge base and industry network. Since its inception, the company has secured significant financial backing, reflecting investor confidence in its business model and the market's potential. It completed an angel round of nearly 50 million yuan, followed by a pre-A round of over 200 million yuan in April 2022, led by Guoshou Equity and Junlian Capital. A subsequent Series A round in December 2022 raised an additional $24.4 million, bringing its total funding to $57.1 million with investors including MSA, Puhua Capital, and China Life Investment. This capital is primarily being deployed to expand its experimental animal resource base and laboratory facilities.
Lingfu Biotechnology's core business revolves around the provision and development of large animal models for disease research, serving clients such as research institutions and hospitals. Its offerings encompass a comprehensive range of experimental animals, including beagle dogs, marmosets, cynomolgus monkeys, and miniature pigs. Beyond simply supplying animal models, the company provides a suite of value-added scientific research services. These services include animal behavior analysis, imaging, testing, foster care, and decontamination, effectively offering an integrated platform for preclinical research. The company aims to create a complete industrial chain solution, covering everything from the experimental animals themselves to sophisticated animal models and high-value research services, supporting crucial drug development processes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.7/100
- Industry
- Food
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2023 | — | — | Sanya Yazhou Bay Venture Capital · Hainan Rongzhi Fund · SDIC Venture Capital | ↗ |
| SERIES A✓Equity / VC | Dec 2022 | $23M | $94M | Beijing Saifu Pharmaceutical Research Institute · Sanya Yazhou Bay Venture Capital · Legend Capital · MSA Capital | ↗ |
Growth signals
Latest recorded traffic for Beijing Lingfu Biotechnology is 140 monthly website visits, up 250% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Lingfu Biotechnology in its local ecosystem
The Beijing Lingfu Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- BIBeijing Saifu Pharmaceutical Research Institute
- SCSanya Yazhou Bay Venture Capital
Legend Capital
MSA Capital- PCPuhua Capital
- HFHainan Rongzhi Fund
SDIC Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Lingfu Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Lingfu Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










